This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Provention Bio Dirección
Dirección controles de criterios 3/4
Información clave
Ashleigh Palmer
Chief Executive Officer (CEO)
US$2.3m
Compensación total
| Porcentaje del salario del CEO | 29.8% |
| Permanencia del CEO | 6.5yrs |
| Participación del CEO | 2.7% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 3.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10
Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2022 | US$2m | US$675k | -US$114m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$104m |
| Dec 31 2021 | US$2m | US$613k | -US$114m |
| Sep 30 2021 | n/a | n/a | -US$121m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$118m |
| Dec 31 2020 | US$2m | US$595k | -US$99m |
| Sep 30 2020 | n/a | n/a | -US$77m |
| Jun 30 2020 | n/a | n/a | -US$55m |
| Mar 31 2020 | n/a | n/a | -US$45m |
| Dec 31 2019 | US$4m | US$500k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$38m |
| Jun 30 2019 | n/a | n/a | -US$34m |
| Mar 31 2019 | n/a | n/a | -US$33m |
| Dec 31 2018 | US$584k | US$425k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$25m |
| Jun 30 2018 | n/a | n/a | -US$21m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$778k | US$290k | -US$9m |
Compensación vs. Mercado: Ashleigh's total compensation ($USD2.27M) is below average for companies of similar size in the US market ($USD5.37M).
Compensación vs. Ingresos: Ashleigh's compensation has increased whilst the company is unprofitable.
CEO
Ashleigh Palmer (59 yo)
6.5yrs
Permanencia
US$2,266,108
Compensación
Mr. Ashleigh W. Palmer, B.Sc., M.B.A., is Co-Founder, President, Chief Executive Officer and Director of Provention Bio, Inc. since October 4, 2016. Mr. Palmer served as Chief Executive Officer and Preside...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 6.5yrs | US$2.27m | 2.71% $ 64.2m | |
| Co-Founder & Chief Scientific Officer | 6.5yrs | US$1.16m | 1.13% $ 26.8m | |
| Chief Medical Officer | 3.3yrs | US$1.16m | 0.074% $ 1.7m | |
| Chief Financial Officer | 1.3yrs | US$2.24m | sin datos | |
| Chief Operations Officer | 1.3yrs | sin datos | sin datos | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Chief Legal Officer | 2.7yrs | sin datos | sin datos | |
| Vice President of Corporate Communications | no data | sin datos | sin datos | |
| Vice President Marketing | no data | sin datos | sin datos | |
| Chief People Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 3.7yrs | sin datos | sin datos | |
| Chief Commercial Officer | 3.3yrs | US$5.61m | 0% $ 0 |
3.3yrs
Permanencia media
46yo
Promedio de edad
Equipo directivo experimentado: PRVB's management team is considered experienced (3.3 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 6.5yrs | US$2.27m | 2.71% $ 64.2m | |
| Independent Director | 4.6yrs | US$168.04k | 0.021% $ 499.6k | |
| Independent Director | 2.9yrs | US$159.08k | 0% $ 0 | |
| Independent Chairman | 5yrs | US$198.36k | 0.0079% $ 187.3k | |
| Independent Director | 2.7yrs | US$150.22k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | sin datos |
3.8yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: PRVB's board of directors are considered experienced (3.8 years average tenure).